Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/EP2011/069476, filed Nov 4, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,363,307 | Methods of Treating Psoriatic Arthritis Using IL-17 Antagonists In force · Medium confidence UsedRemaining | Novartis AG | In force | Medium confidence | ||
| US 12,465,635 | Methods of Treating Inflammatory Arthritis Using Secukinumab In force · High confidence | Novartis AG | In force | High confidence | ||
| US 12,594,333 | Methods of Treating Inflammatory Arthritis Using IL-17 Antagonists In force · High confidence | Novartis Pharma AG | In force | High confidence | ||
| US 11,534,491 | Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists In force · High confidence | Novartis AG | In force | High confidence | ||
| US 9,744,234 | Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists In force · High confidence | Novartis Pharma AG | In force | High confidence | ||
| Application 16/439,423 | Methods of Treating Psoriatic Arthritis Using IL-17 Antagonists Abandoned Abandoned Dec 18, 2021 | Novartis AG | Abandoned | Abandoned Dec 18, 2021 | ||
| Application 17/127,758 | Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists Abandoned Abandoned Nov 18, 2022 | Novartis AG | Abandoned | Abandoned Nov 18, 2022 | ||
| Application 17/165,729 | Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists Abandoned Abandoned Oct 22, 2022 | Novartis AG | Abandoned | Abandoned Oct 22, 2022 | ||
| Application 18/048,797 | Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists Abandoned Abandoned Oct 27, 2026 | Novartis Pharma AG | Abandoned | Abandoned Oct 27, 2026 | ||
| Application 18/061,221 | Methods of Treating Ankylosing Spondylitis Using IL-17 Antagonists Pending Not granted | Novartis Pharma AG | Pending | Not granted | ||
| 1 more record in this group · Pro | ||||||
10 of 11 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 11.
2 of these are in force and held by Novartis Pharma AG.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.